Studying the impact of Lorazepam on approach/avoidance behaviour in healthy individuals

Not Applicable

Completed

• Conditions: Validation of a human version of the rodent approach/avoidance conflict model; Mental and Behavioural Disorders

• Registration Number: ISRCTN12590498
• Lead Sponsor: Psychiatric University Hospital (Psychiatrische Universitätsklinik) Zürich (PUK ZH)

Brief Summary

1. 2017 results in https://www.ncbi.nlm.nih.gov/pubmed/28364943 (added 23/01/2019)

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2014-12-08
• Study Completion: 2015-08-01
• Last Update Posted: 11 February 2019

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

1. Informed Consent as documented by signature
2. Age 18 – 40 years

Exclusion Criteria

1. Contraindications to benzodiazepines: dependence or former dependence, history of allergic reactions, history of hypotonia associated with benzodiazepines
2. Use of any drugs in the 2 weeks prior to the study with the exception of contraceptive drugs and incidental use of NSARs or paracetamol
3. Women who are pregnant or breast feeding
4. Intention to become pregnant during the course of the study
5. Lack of safe contraception, defined as: Female participants of childbearing potential, not using and not willing to continue using a medically reliable method of contraception for the entire study duration, such as oral, injectable, or implantable contraceptives, or intrauterine contraceptive devices, or who are not using any other method considered sufficiently reliable by the investigator in individual cases
6. Other clinically significant concomitant disease states (e.g., renal failure, hepatic dysfunction, cardiovascular disease, etc.)
7. Any history of psychiatric, neurological, dependence or systemic/rheumatic disease
8. Known or suspected non-compliance, drug or alcohol abuse
9. Inability to follow the procedures of the study, e.g. due to language problems
10. Participation in another study with investigational drug within the 30 days preceding and during the present study
11. Previous enrolment into the current study
12. Members of the study team and their family members and dependents

Study & Design

• Study Type: Interventional
• Study Design: Not specified